THANK YOU FOR SUBSCRIBING
Corval has introduced a cloud-based commercialization planning platform for early-to mid-stage biopharmaceutical enterprises.
FREMONT, CA: Corval LLC has launched a cloud-based commercialization planning platform for early-to mid-stage biopharmaceutical enterprises. The platform, which industry veterans developed with extensive experience in biopharma commercialization, offers a technology-based strategy to commercialization planning that help management focus on strategic objectives, timing, and future resourcing requirements.
"I have spent my entire career in this space and been exposed to the many challenges facing early- to mid-stage biopharma companies, particularly, how the lack of in-house expertise and constrained resources can threaten the ability to know what to do when," said Sue Nemetz, Founder and CEO of Corval and CEO of The NemetzGroup LLC, a strategic consultancy that has supported the progression of over 100 companies with assets at every phase of development.
"As a biotech CEO and investor, I have seen many companies get mired in the commercialization planning process. Corval, built upon the wealth of knowledge and experience from The NemetzGroup, will help ensure biotech executive teams dont miss any critical steps on their path to market," added Abbie Celniker, a Partner at Third Rock Ventures.
The Corvals platform is based on years of biopharmaceutical commercialization experience. More than 75,000 data points drive suggestions across the development timeline and account for the particular conditions of every asset's commercial strategy.
"As a firm believer in early commercialization planning, the value of Corval was immediately clear to me. Corval allowed our newly formed team to quickly align on key assumptions and strategic decisions so we could hit the ground running with clarity and confidence on the road ahead," said Kerrie Brady, CEO of OcuTerra Therapeutics, a clinical-stage biopharmaceutical company and early adopter of the Corval Platform.
Nemetz added, "With Corval, companies can rapidly produce a comprehensive and customized commercialization plan and forge ahead on the work of getting treatments to patients in need."